Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 4Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 132Ovarian Neoplasms 109Endometrial Neoplasms 80Uterine Cervical Dysplasia 19Papillomavirus Infections 17Breast Neoplasms 16Fallopian Tube Neoplasms 15Carcinoma, Ovarian Epithelial 15Colorectal Neoplasms 13Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Vulvar Neoplasms 10Neoplasm Metastasis 10Recurrence 9Prostatic Neoplasms 9Endometrial Hyperplasia 9Cervical Cancer Screening 9Acquired Immunodeficiency Syndrome 8Uterine Neoplasms 7Stomach Neoplasms 7Squamous Intraepithelial Lesions 6Locally Advanced Cervical Cancer 6Anus Neoplasms 6Vaginal Neoplasms 5Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Pelvic Neoplasms 5Pancreatic Neoplasms 5Melanoma 5

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Platinum-resistant Recurrent Ovarian Cancer × Gynecologic × Clear all
NCT06509971 2024-07-19

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

West China Second University Hospital

Phase 2 Not yet recruiting
39 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡